ProMetic Life Sciences Inc. (PLI) Given Outperform Rating at Royal Bank Of Canada
A number of other equities research analysts also recently commented on the company. TD Securities reiterated a speculative buy rating and issued a C$4.50 target price on shares of ProMetic Life Sciences in a research report on Thursday, October 27th. Scotiabank restated an outperform rating and set a C$5.00 price objective on shares of ProMetic Life Sciences in a research report on Thursday, October 27th. Bloom Burton restated a hold rating on shares of ProMetic Life Sciences in a research report on Thursday, October 13th. Finally, CIBC decreased their price objective on ProMetic Life Sciences from C$5.00 to C$4.85 in a research report on Thursday, August 25th. Two analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. The stock has a consensus rating of Buy and a consensus price target of C$4.84.
ProMetic Life Sciences (TSE:PLI) traded up 4.09% during midday trading on Wednesday, hitting $2.80. The company had a trading volume of 877,830 shares. ProMetic Life Sciences has a 52 week low of $1.88 and a 52 week high of $3.62. The company’s market capitalization is $1.69 billion. The stock has a 50 day moving average price of $2.89 and a 200 day moving average price of $2.94.
ProMetic Life Sciences Company Profile
ProMetic Life Sciences Inc (ProMetic) is a Canada-based biopharmaceutical company. The Company has two segments: Small Molecule Therapeutics and Protein Technology. The Company offers its technology platform for large-scale drug purification of biologics, drug development, proteomics and the elimination of pathogens to various industries, and uses its own affinity technology that provides for extraction and purification of therapeutic proteins from human plasma in order to develop therapeutics and orphan drugs.
Receive News & Stock Ratings for ProMetic Life Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProMetic Life Sciences Inc. and related stocks with our FREE daily email newsletter.